A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

Eligibility Criteria

• * Age ≥ 18 years
• * Willing and able to give written informed consent
• * Pathological documentation of tumor type and mutation prior to the first dose of study drug(s), for applicable cohorts.
• * There is no available standard systemic therapy available for the patient's tumor histology and/or molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy
• * Able to swallow oral medication
• * Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
• * Adequate cardiovascular, hematological, liver, and renal function
• * Willing to comply with all protocol-required visits, assessments, and procedures
• * Previous treatment with a RAS inhibitor
• * Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-0015
• * Received prior palliative radiation within 14 days of Cycle 1, Day 1
• * Have primary central nervous system (CNS) tumors
• * Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption
• * Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs
• * Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial